Friday, September 16, 2016

#InvestorIdeas Adds #Stocks to Directories: #Mining, #Agriculture, #Technology, #LOHAS, #Defense and #RenewableEnergy

#InvestorIdeas Adds #Stocks to Directories: #Mining, #Agriculture, #Technology, #LOHAS, #Defense and #RenewableEnergy



Point Roberts, WA, Delta BC – September 16, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories in mining, renewable energy, agriculture, defense , tech and LOHAS.   

Companies within the renewable energy sector include a renewable materials company, battery and energy storage stocks, lithium stocks and UGE International Ltd (TSX:UGE.V;  OTC:UGEIF) which is involved in the LED Lighting, Wind and Solar Power sectors.

Additions were also made to the mining stocks list including new lithium stocks and North American companies mining in Mexico.

Other updates include a LOHAS clothing company, an agriculture company focusing on pest management and plant health, a defense company that is focused on improving security at public schools and a cloud-computing technology company.


Mining Companies Added:
Kitrinor Metals Inc. (TSX:KIT.V), Rio Silver Inc. (TSX:RYO.V), GoGold Resources Inc. (TSX:GGD.TO), NioCorp Developments Ltd. (TSX:NB.TO; OTC:NIOBF), Almadex Minerals Inc. (TSX:AMZ.V), Iconic Minerals Ltd. (TSX:ICM.V), Lovitt Resources Inc. (TSX:LRC-H.V) and Pure Energy Minerals Limited (TSX:PE.V)

Renewable Energy Companies Added:
BioAmber Inc. (NYSE: BIOA), EnSync, Inc. (NYSE MKT: ESNC), Ideal Power, Inc. (NasdaqCM:IPWR) , UGE International Ltd. (TSX:UGE.V) (OTC:UGEIF), Iconic Minerals Ltd. (TSX:ICM.V) (lithium) and Pure Energy Minerals Limited (TSX:PE.V) (lithium)

LOHAS Company Added:
Gildan Activewear Inc. (NYSE:GIL; TSX:GIL.TO) is a leading manufacturer and marketer of quality branded basic family apparel, including T-shirts, fleece, sport shirts, underwear, socks, hosiery, and shapewear. The Company sells its products under a diversified portfolio of company-owned brands, including the Gildan®, Gold Toe®, Anvil®, Comfort Colors®, Alstyle®, Secret®, Silks®, Kushyfoot®, Secret Silky®, Peds®, MediPeds® and Therapy Plus™ brands. Sock products are also distributed through the Company's exclusive U.S. sock license for the Under Armour® brand, and a wide array of products is also marketed through a global license for the Mossy Oak® brand. The Company sells its products through two primary channels of distribution, namely printwear and retail markets. The Company distributes its products in printwear markets in the U.S., Canada, Europe, Asia-Pacific and Latin America. In retail markets, the Company sells its products to a broad spectrum of retailers primarily in the U.S. and Canada and also manufactures for select leading global athletic and lifestyle consumer brands. Gildan owns and operates vertically-integrated, large-scale manufacturing facilities which are primarily located in Central America, the Caribbean Basin, North America and Bangladesh. These facilities are strategically located to efficiently service the quick replenishment needs of its customers in the printwear and retail markets. Gildan has over 48,000 employees worldwide and is committed to industry-leading labour and environmental practices throughout the Company's supply chain.

Agriculture Company Added:
Marrone Bio Innovations, Inc. (NasdaqGM:MBIIstrives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have four products for agriculture on the market (Regalia®, Grandevo®, Venerate® and Majestene®), and also distribute Bio-tam 2.0® for Isagro USA in the western U.S. MBI also markets Zequanox® for invasive mussels for water markets. We also have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe.

Defense Company Added:
Defense Technologies International Corp (OTC: DTII) through its wholly owned subsidiary ‘Defense Technology Corporation’, a developer of security technologies presents its first product, the ‘Offender Alert Passive Scan™’ a new non-evasive Scanner to improve security especially at schools as well as other venues of public assembly. DTII’s core ideology is to provide superior solutions for today’s new world risks and threats. DTII is positioned to enter the, until now, untapped public school market segment for threat detection security.

Technology Company Added:
Violin Memory®, Inc. (NYSE: VMEM) the disruptive innovator in All Flash Arrays, is revolutionizing how businesses operate by enabling storage technology to Be Instrumental to their company by changing the SLAs and capabilities of private, hybrid and public cloud environments. The Flash Storage Platform™, powered by Concerto OS™, a fully integrated storage operating system, is the industry leader in the combination of every significant category measured in all flash arrays: low latency, affordability, density, scalability and performance. With tightly integrated data services, the Violin Flash Storage Platform provides a unique combination of data protection, business continuity, and data reduction services onto a flexible, uniquely scalable solution called Scale Smart™, delivering significant CAPEX and OPEX savings. Founded in 2005, Violin Memory is headquartered in Santa Clara, California.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Investorideas is currently offering a back-to-school/back-to-work special for investors and traders – all PDF directories are currently on sale for $10 each – a savings of over 65%! (regular price $29)
Special offer link- Shop: September 14-21

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411












Thursday, September 15, 2016

Investor Ideas Stock Directories -Water, Renewable Energy, Biotech, Tech, Mining Stocks Profiled for Active Traders and Investors


Investor Ideas Stock Directories -Water, Renewable Energy, Biotech, Tech, Mining Stocks Profiled for Active Traders and Investors 

Point Roberts, WA, Delta BC – September 15, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors reminds traders and investors of its  back- to-school and back- to- work special for its comprehensive stock directories.. 

Investorideas.com stock directories feature hundreds( up to over 1000 ) of publicly traded company profiles in leading sectors including mining, tech, biotech, water, renewable energy, defense, oil and gas and others. The directories that are provided in PDF format are emailed to investors following purchase. The directories, regularly retail for $29 and will be available for $10 for the week of September 14th-21st
 

Special offer link- Shop: September 14-21

Investorideas.com global stock directories are also part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.


About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Contact Investorideas.com
800-665-0411











Wednesday, September 14, 2016

SilverCrest (TSXV: $SIL.V) Announces Remaining Phase I Drilling Results from Las Chispas Project; Further Drilling Confirms Grade Continuity in Las Chispas Vein

SilverCrest (TSXV: $SIL.V) Announces Remaining Phase I Drilling Results from Las Chispas Project; Further Drilling Confirms Grade Continuity in Las Chispas Vein



Vancouver - September 14, 2016 (Investorideas.com Newswire) SilverCrest Metals Inc. (TSXV: $SIL.V) is pleased to announce the results of the remaining drill holes from Phase I drilling for the Las Chispas Project. The Las Chispas Project ("Las Chispas") is located in Sonora State, Mexico and is in a historic silver-gold mining district which presently hosts two nearby precious metal producers. Historic information indicates that of the fourteen historically reported veins at Las Chispas, only three veins, the Las Chispas, William Tell and Babicanora, had documented production, which occurred between 1880 and 1930.

SilverCrest’s initial focus is on these three veins. To the Company’s knowledge, none of the known veins have been drilled prior to the Company’s Phase I drill campaign. For more information, please refer to our website at http://www.silvercrestmetals.com.

Dunham Craig, P.Geo., Interim CEO remarked, "The remaining drill hole results from the Phase I drill program intercepted the Las Chispas vein which has further demonstrated continuity of high grades and potential mineable thicknesses. Phase II exploration work will continue to define the Las Chispas vein for resource estimation expected in H1 2017. As we continue to systematically explore this district-wide discovery with multiple undrilled epithermal veins, we could potentially have several more discoveries. The Babicanora area (no previous drilling), immediately adjacent to Las Chispas and William Tell veins, is considered the largest target in the district and will be tested in Phase II exploration."

The most substantial core drilling results from the remainder of the Phase 1 holes are 1.0 metres wide grading 1.55 grams per tonne ("gpt") gold ("Au") and 706.0 gpt silver ("Ag"), or 822.2 gpt silver equivalent ("AgEq"* uncut, undiluted, see attached Figure). The following table summarizes the most significant drill assay results (uncut, undiluted) for the Las Chispas vein only;


Note: all numbers are rounded.
*AgEq based on 75 (Ag):1 (Au) and 100% metallurgical recovery.
** All holes were drilled at perpendicular angles to mineralization with no adjustments required. Minimum sample width is 1.0 m.
*** Intercept is for a new consistent vein in the footwall of Las Chispas Vein as previous drilled and defined.

All assays were completed by ALS Chemex in Hermosillo, Mexico, and North Vancouver, BC.
All drill holes have intercepted quartz stockwork veinlets, veining and/or breccia.

Deeper vein intercepts into the Las Chispas vein, including holes LC16-12, 13, 14 and 15, intercepted quartz veining and stockwork. Grades for those intercepts were below 150 gpt AgEq. Further work is required to depth to better understand the precious metal zone below 300 metres from surface. Drill-intercepted mineralization at Las Chispas vein currently suggests a precious metal zone of at least 300 metres in depth.

The first NI43-101 technical report (non-resource) is currently being completed and should be available in Q4 2016. Based on the recent success of the Las Chispas Phase I program and subsequent announced discoveries, the Company is targeting a first resource estimation to be announced in H1 2017 along with a 100,000 tonne bulk sampling plan to form the basis for a preliminary economic assessment.

Underground rehabilitation work continues as scheduled with approximately 5 kilometres of the estimated existing 11.5 kilometres reopened.

The Company is completing final permitting for the Phase II exploration program. Work is anticipated to commence in Q4 2016.

The Qualified Person under National Instrument 43-101 Standards of Disclosure for Mineral Projects for this news release is James Barr, P.Geo, who is independent of SilverCrest and has approved its contents.


UPCOMING EVENTS
SilverCrest Metals will be attending and presenting at the Precious Metals Summit in Beaver Creek, Colorado from September 14 to 16, 2016. The Precious Metals Summits are exclusive by-invitation events designed to help institutional investors and corporate development executives from senior mining companies identify some of the most prospective precious metals producers, developers and explorers from around the globe.


ABOUT SilverCrest Metals INC.
SilverCrest is a Canadian precious metals exploration company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions and targeting production in Mexico’s historic precious metal districts. The Company is led by a proven management team in all aspects of the precious metal mining sector, including the pioneering of a responsible “phased approach” business model taking projects through discovery, finance, on time and on budget construction, and production with subsequent increased value to shareholders.  

FORWARD-LOOKING STATEMENTS
This news release contains “forward-looking statements” within the meaning of Canadian securities legislation. These include, without limitation, statements with respect to: the strategic plans, timing and expectations for the Company’s exploration, rehabilitation and drilling programs of the Las Chispas Project; information with respect to high grade areas and size of veins projected from underground sampling results; and the accessibility of future mining at the Las Chispas Project. Such forward‑looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: the conditions in general economic and financial markets; availability of skilled labour; timing and amount of expenditures related to rehabilitation and drilling programs; and effects of regulation by governmental agencies. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors including: the timing and content of work programs; results of exploration activities; the interpretation of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Dunham L. Craig, P.Geo., Director
Interim CEO
SilverCrest Metals Inc.

Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
SilverCrest Metals Inc.
Fred Cooper, Investor Relations
Telephone: +1 (604) 694-1730
Fax: +1 (604) 694-1761
Toll Free: 1-866-691-1730 (Canada & USA)
570 Granville Street, Suite 501, Vancouver, British Columbia V6C 3P1


More info on SIL.V at Investorideas.com: http://www.investorideas.com/CO/SILV/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure:Investorideas.com is compensated by SilverCrest Metals Inc for annual news publishing effective January 2016.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.





Friday, September 09, 2016


Investor Ideas Newswire Goes #AI and Joins the Grid Artificial Intelligence #Web Developer Revolution  


Point Roberts, WA, Delta BC – September 9, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces it has added new  distribution for the Investor Ideas Newswire with a new site hosted on the Grid https://thegrid.io/, a newly launched artificial website building company.

Investor Ideas was one of the founding members and beta testers of the personal AI web developer. The Grid has finalized beta testing and recently went live, add new features and tools.

“The site is still a work in progress for us as we get to wrap our heads and hands around the artificial intelligence that it provides but we felt that we wanted to test first- hand how this new technology works “ said founder D. Zant of Investor Ideas.


Investor Ideas Newswire on the Grid

News Submission: upload news to Investor Ideas Newswire


About the Grid
This is not another do-it-yourself website builder. The Grid harnesses the power of artificial intelligence to take everything you throw at it - videos, images, text, urls and more - and automatically shape them into a custom website unique to you. As your needs grow, it evolves with you, effortlessly adapting to your needs. Want to add e-commerce? Social feeds? A different layout? The Grid just takes care of it. This is not a website builder. This is your personal AI web developer. Its first masterpiece is the website you're looking at right now. Its next one could be yours.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Contact Investorideas.com
800-665-0411











Aethlon Medical (NASDAQ: $AEMD) CEO Note: The Dilemma in Funding Zika and Other Pandemic Therapies

Aethlon Medical (NASDAQ: $AEMD) CEO Note: The Dilemma in Funding Zika and Other Pandemic Therapies


SAN DIEGO - September 9, 2016 (Investorideas.com newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

After a seven-week vacation, the U.S. Congress and Senate returned to work on Tuesday and immediately restarted the fight to advance a Zika virus funding program. Beyond normal political posturing, government officials face the dilemma of whether to allocate resources to support the advancement of traditional drugs and vaccines or emerging broad-spectrum therapies. As it relates to viral pandemics, there is often an assumptive complacency that drug and vaccine cures are just a matter of spending sufficient capital resources. In reality, the effort to align a disease-specific drug or vaccine with an emerging pandemic threat is immensely challenging and not often successful. Especially in the case of a virulent pathogen that may prohibit human studies from being conducted to demonstrate treatment efficacy.

Emerging pandemics represent significant threats to mankind and Zika is just one of many active pathogen threats not addressed with a traditional drug and vaccine. Beyond pathogens known to be infectious to man, a proliferation of international travel, urban crowding and global warming are expected to accelerate the emergence of new pandemic threats in the future. Then, there is the issue of pathogens created and released by man as agents of bioterrorism.

Our government has an opportunity to inspire the biotechnology industry to fuel innovation through the development of broad-spectrum treatment countermeasures that can cross the boundaries of treating different strains, species and families of life-threatening viral pathogens. The facts underlying the challenge of aligning a disease-specific drug or vaccine with each pathogen threat reinforces the need for broad-spectrum therapeutic innovation.

Statistical Improbability
It is statistically improbable for traditional pathogen-specific drugs and vaccines to be developed, proven to be effective, manufactured and then delivered in a timeframe necessary to combat a life-threatening bioterror or pandemic threat. As pathogen outbreaks cannot be predicted, the current universe of therapeutic developers is extremely limited as there is no commercial incentive to develop such countermeasures from a business model perspective.

Conversely, the U.S. Food and Drug Administration (FDA) reports that hundreds and sometimes thousands of chemical drug compounds must be made and tested to find one that can achieve a desirable result without serious side effects. To further support this statement, the FDA website reports that the Pharmaceutical Research and Manufacturers of America estimates that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and only 1 of those 5 may be safe and effective enough to be approved. Beyond those statistics, expectations for traditional countermeasures should further be tempered as each pathogen threat may require multiple drug mechanisms to address the corresponding pathogen threat. In regards to Zika, there are likely no more than a handful of candidate drug compounds that have been proposed to treat the virus.

Too Many Threats
Of the more than 300 viruses known to be infectious to man, only a small fraction are addressed with a proven antiviral drug or vaccine countermeasure. It has been estimated that our government has spent more than $80 billion to defend against biological threats since 2001. Yet, just one of 13 viruses classified as "Category A" have been addressed with a treatment countermeasure. The National Institute for Allergy and Infectious Diseases (NIAID) considers "Category A" pathogens to be biological agents that pose the highest risk to national security and public health as they are easily disseminated, result in high mortality rates, and cause public panic and social disruption. Furthermore, the development of disease-specific drug and vaccine countermeasure against unknown viral threats is not possible until the pathogen has either emerged naturally or been released by man as an agent of bioterrorism.

Inability to Demonstrate Effectiveness
Perhaps the greatest challenge in advancing a disease-specific drug or vaccine is the inability to ethically or feasibly conduct controlled human studies that demonstrate treatment efficacy against a virulent threat. As a result, treatment efficacy is required to be demonstrated in animal models, which in many cases either don't exist or don't equate to treatment efficacy in humans. As a result, at-risk populations (those most likely to need protection) such as pregnant women (a primary treatment target for Zika), children, elderly adults and those with other underlying medical conditions are not recommended to receive therapeutic candidates that are not proven to be effective in humans studies.

A Shift Towards Broad-Spectrum Treatment Countermeasures
The challenge of aligning a drug and vaccine with each pathogen threat has already established an impetus for U.S. government health agencies to support innovative therapeutic mechanisms that can be deployed against a wide-range of pathogen threats. Such evidence is best reflected in the 2015 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan (SIP), which describes the priorities that the U.S. Department of Health and Human Services (HHS) will implement over the next five years to protect against bioterror and emergency pandemic threats. A primary objective of the PHEMCE SIP includes the advancement of platform technology medical countermeasures with broad-spectrum capabilities. We are working to establish the Aethlon Hemopurifier®, which is being advanced clinically in an FDA approved study, as a leading broad-spectrum treatment countermeasure.

The Hemopurifier® is an immunotherapeutic technology designed for the single-use elimination of infectious viruses from the circulatory system. The technology provides a post-exposure treatment strategy to mitigate illness, suffering, and death resulting from exposure to virulent viral pathogens that are often beyond the reach of drug and vaccine therapies. In addition to Zika virus, in vitro studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, which is currently spreading in the U.S. and is responsible for numerous deaths. Vaccinia and Monkey pox, which serve as models for human Smallpox infection, have also been validated. Specific to pandemic influenza threats, we have validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which killed as many as 50 million individuals. In regards to human studies, Hemopurifier therapy has been successfully administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).

Additional studies are currently being conducted to validate the capture of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), which has a fatality rate of approximately 40%, and Marburg Virus, which is classified as a "Category A" bioterror and pandemic threat with a fatality rate exceeding 50%.

Zika and other emerging pandemic viruses represent a significant threat to mankind. We believe that broad-spectrum treatment countermeasures that cross the boundaries of different strains, species and families of viruses, should be the basis for life-saving innovation that will be necessary to combat emerging pandemic threats around the globe. With Congress and the Senate now back at work, the political debate of how to protect against Zika and other pandemics can now continue.


About Aethlon Medical
Aethlon Medical (AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Aethlon is part of the Russell Microcap® Index. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.



The Hemopurifier® in Cancer
Upwards of ninety percent of all cancer-related deaths are attributed to metastasis; the spread of cancer from a primary site of origin to other organs or areas of the body. The mechanism of how tumors metastasize to distant sites in the body has long been one of cancer's greatest mysteries. That mystery was recently solved when circulating particles known as tumor-derived exosomes were discovered to be the seeds that promote the spread and growth of cancer metastasis.

Aethlon initiated its tumor-derived exosome research at a time when the medical community believed exosomes were merely cellular debris with no biological function. Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care. Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes underlying several forms of cancer, including breast, ovarian and metastatic melanoma.

Beyond their role in metastasis, researchers have also published mounting evidence that tumor-derived exosomes contribute to tumorigenesis (the formation of cancer), cancer progression, angiogenesis (creation of blood vessels to fuel tumor growth), immune evasion, and resistance to radiation and chemotherapeutic drugs. Recent discoveries also reveal that exosomes may contribute to bacterial and viral pathogenesis, the progression of Alzheimer and Parkinson's diseases, the spread of prion proteins, and numerous inflammatory conditions.

The Hemopurifier® in Infectious Disease
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.

To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."

Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection. Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.

Aethlon has also demonstrated that the Hemopurifier captures the bacteria toxins lipopolysaccharide (LPS) and lipoteichoic acid (LTA). These studies were conducted under a contract with the Defense Advanced Research Projects Agency (DARPA) related to the treatment of sepsis.



About Exosome Sciences
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical (Nasdaq: AEMD), is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases. The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids. In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection. Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to detect Chronic Traumatic Encephalopathy (CTE) in living individuals. In a study of former National Football League (NFL) players, TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports. TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed. Visit www.exosomesciences.com for additional details.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, including any products relating to the Zika virus, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:
Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
smarg@braincomm.com

Visit this Company: www.AethlonMedical.com

More info on AEMD at Investorideas.com: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD August 11, 2016 – one month of PR. News publication and social media – two thousand five hundred  

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.






#TSX Venture #Stocks Added to Investor ideas: $BLR.V $BOR.V $CRF.V $KNT.V $GSW.V and $LMT.V

#TSX Venture #Stocks Added to Investor ideas:  $BLR.V $BOR.V $CRF.V $KNT.V $GSW.V and $LMT.V


Point Roberts, WA, Delta BC – September 9, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories. 

Companies include natural gas and oil and gas companies, mining companies and a medical diagnostic company.  All stocks are listed on the TSX Venture Exchange.


Energy Companies Added:
Blackhawk Resource Corp. (TSX:BLR.V) is a publicly owned investment manager. It invests in public equity and fixed income markets across North America. It focuses on investing in multiple companies across various sectors. Previous Investments were within the oil and gas, mining and technology and media sectors.

Border Petroleum Limited (TSX:BOR.V) is focused on the development and exploitation of its light oil and gas assets in north central Alberta. Border has an experienced and skilled management team focused on building shareholder value by finding and developing light oil production and reserves.

Mining Companies Added:
Coronet Metals Inc. (TSX:CRF.V), K92 Mining Inc. (TSX:KNT.V) and Green Swan Capital (TSX:GSW.V) 

Biotech Companies Added:
Luminor Medical Technologies Inc. (TSX:LMT.V) is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company's Scout DS® device has been regulatory cleared in certain markets both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411